Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8928186 | 0.89 | CHRM2 (0.63) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL723511 | 0.87 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL30080050 | 0.87 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL4060273 | 0.86 | TAAR1 (0.69) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL833882 | 0.84 | TAAR1 (0.67) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL4949653 | 0.84 | TAAR1 (0.67) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL29986862 | 0.83 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL21002016 | 0.83 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL21002162 | 0.83 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL7638048 | 0.83 | TAAR1 (0.60) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505753-B2 | Inhibitors of D-amino acid oxidase | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2435019-B1 | DODECA-2E,4E-DIENE AMIDES AND THEIR USE AS MEDICAMENTS AND COSMETICS | WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-20150218156-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-06 | — | — | US | disclosed |
| WO-2014025993-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2010021149-A1 | SPIRO COMPOUND CAPABLE OF INHIBITING ACID SECRETION | 武田薬品工業株式会社 (JP) | 2010-02-25 | — | — | WO | disclosed |
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6166082-A | Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5886022-A | TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA | BAYER CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5886043-A | ANTIARTHRITIC AGENTS, ANTITUMOR AGENTS, ANTIINFLAMMATORY AGENTS | BAYER CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5789434-A | ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION | BAYER CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996015096-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
| EP-0256888-B1 | BENZOTHIAZEPINE VASODILATORS HAVING ARALKYL SUBSTITUTION | McNeilab, Inc. (US) | 1991-07-03 | — | — | EP | disclosed |
| US-4729994-A | Benzothiazepine vasodilators having aralkyl substitution | MCNEILAB, INC. (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0256888-A1 | Benzothiazepine vasodilators having aralkyl substitution | McNeilab, Inc. (US) | 1988-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218156-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, GRIN2A | TAAR1 300/4885CHRM2 1655/4885CHRM1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.